Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2-day in-hospital diabetes educational program

Diabetes Care

Volumn 31, Issue 10, 2008, Pages 1949-1954

  Kawahara, Tetsuya ^a,b   Takahashi, Keiichi ^c   Inazu, Tetsuya ^d   Arao, Tadashi ^b   Kawahara, Chie ^b,e   Tabata, Takahiro ^a,b   Moriyama, Hlroyuki ^a   Okada, Yosuke ^b   Morita, Emiko ^b   Tanaka, Yoshiya ^b  

^a Niigata Rousai Hospital   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Takahashi Clinic   (Japan)

^d National Saigata Medical Center   (Japan)

^e Niigata Health Care Association   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES EDUCATION; DISEASE COURSE; EDUCATION PROGRAM; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOSPITAL PATIENT; MIDDLE AGED; MULTICENTER STUDY; PATIENT EDUCATION;

LIPID;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INPATIENTS; LIPIDS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC;

EID: 56149096007     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-2272     Document Type: Article

References (26)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
2. DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621. 1999
3. Fujishima M, Kiyohara Y: Diabetes and cardiovascular disease prospective population survey in Japan: the Hisayama Study. Diabetes 45 (Suppl. 3):S14-S16, 1996
4. Tominaga M, Eguchi H: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
5. Harris MI: Diabetes in America: epidemiology and scope of the problem. Diabetes Carell (Suppl. 3):C11-C14, 1998
6. Knowler WC, Barrett-Connor E, Fowler SE: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl ] Med 346:393-403. 2002
7. Herman WH, Hoerger TJ, Brandle M: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance: Ann Intern Med 142:323-332, 2005
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167. 2003
9. Hansson I, Hender T, Dahlöf B: Prospective randomised open blinded endpoint (PROBE) study: a novel design for intervention trials. Blood Press 1:113-119. 1992
10. Diabetes Treatment Guide Editing Committee: Diabetes Treatment Guide 2003-2004. Tokyo, Japan Diabetes Society, 2003
11. Food Exchange List Editing Committee: Food Exchange List for Diabetes Diet Therapy. Version 6. Tokyo, Japan Diabetes Society, 2002
12. Tuomilehto J, Lindstrom J, Eriksson J: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl] Med 344:1343-1350,2001
13. Gold MR, Siegel JE, Russell LB: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
14. Diabetes Prevention Program Research Group: Cost associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabe- tes Care 26:36-47, 2003
15. Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523, 2003
16. Pan XR, Li GW, Hu YH: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
17. Eriksson KF, Lindgãrde E: Prevention of type 2 (non-insulin- dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmö feasibility study. Diabetolo-gia 34:891-898, 1991
18. ChiassonJL, Josse RG, Gomis R: Acarbose for prevention of type 2 diabetes mellitus the STOP-NIDDM randomised trial. Ean-cet 359:2027-2077, 2002
19. Harris MI: Impaired glucose tolerance-prevalence and conversion to NIDDM. DíabetMedl3:S9-Sll, 1996
20. King H: Study in Tanzania of IGT: effect of regression to the mean. Diabetes Care 15: 114-115, 1992
21. Kadowaki T, Miyake Y, Hagura R: Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Όiabetologia 26:44-49, 1984
22. Modan M, Karasik A, Halkin H: Effect of past and current body mass index on prevalence of glucose intolerance and type 2 non-insulin-dependent diabetes and on insulin response: the Israel study of glucose intolerance, obesity and hypertension. Όiabetologia 29:82-89, 1986
23. Chen HS, Shaw CK, Tseng WP: Prevalence of diabetes mellitus and impaired glucose tolerance in Aborigines and Chinese in eastern Taiwan. Diabetes Res Clín Pract 38:199-205, 1997
24. Diabetes Prevention Program Research Group: The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 25:2165-2171, 2002
25. Cohenx JS: Adverse drug effects, complications, and initial dose of anti hypertensive drugs recommended by the Joint National Committee vs. Physicians Desk Reference. Arch Intern Med 161:880-885, 2001
26. Mitka M: DASH dietary plan could benefit many, but few hypertensive patients follow it. JAMA 298:164-165, 2007